Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Time To Initiate Anti-vascular Endothelial Growth Factor Therapy And Visual Outcome In Central Retinal Vein Occlusion

Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion

Chisato Agata1,2, Shuichiro Aoki1, Kohdai Kitamoto1

  • 1Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Scientific Reports
|July 23, 2024

Related Experiment Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.1K
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

8.4K

View abstract on PubMed

Summary
This summary is machine-generated.

Timely treatment is crucial for central retinal vein occlusion (CVO). Delayed treatment, especially beyond 28 days, significantly worsens visual acuity (VA) prognosis. Early intervention is key for better outcomes in CVO patients.

Area of Science:

  • Ophthalmology
  • Retinal Vascular Diseases

Background:

  • Central retinal vein occlusion (CVO) is a significant cause of vision loss.
  • Understanding the impact of pre-treatment progression on visual acuity (VA) is critical for managing CVO.

Purpose of the Study:

  • To investigate the progression of CVO before treatment initiation.
  • To determine the impact of pre-treatment VA and time to treatment on final visual outcomes.

Main Methods:

  • Retrospective analysis of 54 eyes with acute CVO.
  • Evaluation of visual acuity (VA) at initial visit, initial treatment, and final visit.
  • Analysis of time intervals between initial visit and treatment.

Main Results:

  • VA at initial treatment was a stronger predictor of final VA than initial visit VA.

Related Experiment Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.1K
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

8.4K
  • Treatment initiated >28 days post-visit led to significantly worse VA decline (p=0.006).
  • Treatment between 15-28 days showed greater VA decrease than treatment within 14 days (p=0.026).

    • Conclusions:

    • Pre-treatment VA and timing of intervention significantly influence CVO prognosis.
    • Delayed treatment (>28 days) is associated with poorer visual outcomes.
    • Frequent monitoring for timely treatment initiation is crucial for acute CVO management.